Navigation Links
Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/3/2010

6244,59218,82712,25474,826Total operating expenses 14,81014,18440,58050,833313,138Loss from operations (14,502)(14,162)(40,228)(50,767)(312,171)Other income (expense):Interest income 21471012959,113Interest expense (165)(318)(501)(1,070)(4,307)Total other income (expense) (144)(271)(400)(775)4,806Net loss (14,646)(14,433)(40,628)(51,542)(307,365)Accretion to redemption value of redeemable convertible preferred stock ----(78)Deemed dividend of beneficial conversion for Series C preferred stock----(13,860)Net loss attributable to common stockholders$(14,646)$(14,433)$(40,628)$(51,542)$

(321,303)Net loss per share attributable to common stockholders - basic and diluted $(0.31)$(0.33)$(0.86)$(1.38)Shares used in computing net loss per share attributable to common stockholders – basic and diluted 47,44043,08747,29537,484
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
2. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
3. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
6. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
7. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
8. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
9. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
10. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
11. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. ... health care technology vendors, will take place May 14-17, 2016 in Minneapolis, MN. ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a ... San Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded ... health care providers. 24/7 Care At Home’s agency is one of three top Orange ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... The following is a,statement in response to Patrick Swayze ... CEO of the Pancreatic Cancer,Action Network, the only national ... support, community outreach and,advocacy for a cure., "We ... with,pancreatic cancer and our thoughts go out to him ...
... WASHINGTON and NEWARK, N.J., March 5 Besler,& ... principal, Philip,Besler, have agreed to pay the United ... fraud against the federal Medicare program, the,Justice Department ... the North Brunswick,N.J.-headquartered company counseled hospital clients to ...
... MINNEAPOLIS, March 5 As two of the ... implementation of the Freedom,to Breathe Act, we are ... denounced so-called "theatrical performances" in bars as a,violation ... Freedom to Breathe Act was passed to protect ...
... could use,a little pampering now and then. Think your mom ... Breast Cancer Coalition,(PBCC) and Doneckers of Ephrata take care of ... in 250 words or less why your mom, as a,breast ... and you and your mom could be in for a ...
... says , , WEDNESDAY, March 5 (HealthDay News) -- Variations ... warfarin are important in determining the initial doses of ... is being put to medical use. Last August, the ... say that doctors should consider a genetic test when ...
... Spheris, a leading global,provider of clinical documentation technology and ... results for the fourth quarter,ended December 31, 2007., ... fourth quarter of,2007 after the close of market trading ... call on Thursday, March 27, 2008, at 8:00 a.m. ...
Cached Medicine News:Health News:Patrick Swayze's Diagnosis With Pancreatic Cancer: a Statement From the Pancreatic Cancer Action Network 2Health News:New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud 2Health News:Leading Health Groups Strongly Support the Minnesota Department of Health's Efforts to Enforce Freedom to Breathe Act 2Health News:The Pennsylvania Breast Cancer Coalition Announces Last Chance to Enter 'Makeover for Mom' Contest 2Health News:Genetic Test Predicts Response to Warfarin 2Health News:Genetic Test Predicts Response to Warfarin 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: